DEPTOR and cancer: However, in specific cancer types, such as multiple myeloma and T-cell acute lymphoblastic leukemia, DEPTOR exhibits oncogenic properties by activating AKT to alleviate the negative feedback effect of the mTORC1 substrate, S6K1, on IRS1/PI3K signaling7.